Probity Advisors Inc. Has $1.74 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Probity Advisors Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,707 shares of the company’s stock after buying an additional 179 shares during the quarter. Probity Advisors Inc.’s holdings in Johnson & Johnson were worth $1,735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at $27,000. MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at about $43,000. Fairfield Financial Advisors LTD purchased a new position in Johnson & Johnson during the second quarter worth about $46,000. Fairway Wealth LLC grew its position in Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after purchasing an additional 228 shares in the last quarter. Finally, Quarry LP purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $49,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Finally, TD Securities reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $175.93.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $164.47 on Thursday. The stock has a fifty day moving average of $162.81 and a 200-day moving average of $154.59. The stock has a market cap of $395.83 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the business posted $2.66 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.